Summary
3M Company reported a significant net loss for the second quarter and first six months of 2023, primarily driven by a substantial pre-tax charge of $10.3 billion related to the proposed settlement for PFAS-related public water system claims. This charge overshadowed operational performance, leading to a reported net loss attributable to 3M of $6.84 billion ($12.35 loss per share) for the quarter and $5.87 billion ($10.60 loss per share) for the first six months. Excluding these significant litigation charges and other special items, the adjusted loss per share was $2.17 for the quarter, indicating underlying operational pressures. Net sales decreased by 4.3% in the second quarter and 6.7% year-to-date, with broad-based declines across most business segments, particularly in Transportation and Electronics and Health Care, though Safety and Industrial saw improved adjusted operating income margins due to lower litigation costs. The company is navigating substantial legal and environmental liabilities, notably the PFAS settlement and ongoing litigation related to Combat Arms earplugs. The resolution of these matters represents a significant financial impact and a key focus for management. Despite the reported losses, 3M continues its strategic initiatives, including the planned spin-off of its Health Care business and ongoing restructuring actions aimed at improving efficiency. The company's balance sheet remains strong, with sufficient liquidity to manage its obligations.
Financial Highlights
53 data points| Revenue | $6.28B |
| Cost of Revenue | $3.73B |
| Gross Profit | $2.56B |
| SG&A Expenses | $11.62B |
| Operating Expenses | $15.64B |
| Operating Income | -$9.36B |
| Interest Expense | $144.00M |
| Net Income | -$6.84B |
| EPS (Basic) | $-12.35 |
| EPS (Diluted) | $-12.35 |
| Shares Outstanding (Basic) | 553.90M |
| Shares Outstanding (Diluted) | 553.90M |
Key Highlights
- 1Significant net loss reported for the quarter and year-to-date, heavily impacted by a $10.3 billion pre-tax charge for PFAS settlement.
- 2Net sales declined by 4.3% year-over-year for the second quarter and 6.7% year-to-date, reflecting broad-based weakness across segments.
- 3Adjusted earnings per share (excluding special items) was a loss of $2.17 for the quarter, indicating ongoing operational challenges.
- 4Safety and Industrial segment saw a significant year-over-year improvement in adjusted operating income margins, largely due to reduced litigation expenses.
- 5Transportation and Electronics segment faced an 8.0% decline in sales year-to-date, impacted by softness in electronics and other end-markets.
- 6Health Care segment sales decreased by 5.2% year-to-date, with challenges in biopharma demand and hospital budgets.
- 7The company continues to manage substantial litigation liabilities, including the major PFAS settlement and Combat Arms earplugs litigation, which have a material financial impact.